SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
-9.67%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$340M
AUM Growth
+$340M
(-9.2%)
Cap. Flow
-$481K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
55.44%
Holding
66
New
16
Increased
14
Reduced
10
Closed
19
Top Buys
| 1 |
Immunocore
IMCR
|
$11.5M |
| 2 |
Immunovant
IMVT
|
$10.2M |
| 3 |
Merck
MRK
|
$10.2M |
| 4 |
GSK
GSK
|
$9.47M |
| 5 |
Arcellx
ACLX
|
$7.75M |
Top Sells
| 1 |
Insmed
INSM
|
$12.4M |
| 2 |
Eli Lilly
LLY
|
$11.7M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
$11.5M |
| 4 |
Roivant Sciences
ROIV
|
$8.89M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$8.08M |
Sector Composition
| 1 | Healthcare | 99.56% |
| 2 | Financials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fulcrum Therapeutics
FULC
$348M
| $4.32M | 1.27% |
696,464
+289,356
| +71% | +$1.79M |
|
27
Nurix Therapeutics
NRIX
$698M
| $4.24M | 1.25% |
+203,273
| New | +$4.24M |
|
28
Pyxis Oncology
PYXS
$79.4M
| $3.98M | 1.17% |
1,202,675
-591,520
| -33% | -$1.96M |
|
29
Janux Therapeutics
JANX
$1.36B
| $3.89M | 1.14% |
92,949
-28,693
| -24% | -$1.2M |
|
30
IDEAYA Biosciences
IDYA
$2.18B
| $3.57M | 1.05% |
101,787
+14,394
| +16% | +$505K |
|
31
Spyre Therapeutics
SYRE
$1B
| $3.54M | 1.04% |
150,450
+88,197
| +142% | +$2.07M |
|
32
Perspective Therapeutics
CATX
$250M
| $3.43M | 1.01% |
+343,810
| New | +$3.43M |
|
33
Jasper Therapeutics
JSPR
$44.7M
| $3.26M | 0.96% |
143,775
+14,564
| +11% | +$331K |
|
34
Black Diamond Therapeutics
BDTX
$160M
| $3.14M | 0.92% |
+674,198
| New | +$3.14M |
|
|
VIGL
35
DELISTED
Vigil Neuroscience
VIGL
| $2.98M | 0.88% |
+744,412
| New | +$2.98M |
|
36
Neurogene
NGNE
$277M
| $2.86M | 0.84% |
+78,601
| New | +$2.86M |
|
|
SLN
37
Silence Therapeutics
SLN
$229M
| $2.37M | 0.7% |
+124,866
| New | +$2.37M |
|
38
Protara Therapeutics
TARA
$122M
| $2.05M | 0.6% |
984,113
+815,671
| +484% | +$1.7M |
|
|
BBOT
39
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$724M
| $2.04M | 0.6% |
200,000
| – | – |
|
40
Surrozen
SRZN
$105M
| $1.57M | 0.46% |
+143,510
| New | +$1.57M |
|
|
PCSC
41
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $1.51M | 0.44% |
+150,000
| New | +$1.51M |
|
42
Praxis Precision Medicines
PRAX
$946M
| $1.21M | 0.36% |
29,259
+2,366
| +9% | +$97.9K |
|
43
AnaptysBio
ANAB
$576M
| – | – |
-269,548
| Closed | -$6.07M |
|
44
Astria Therapeutics
ATXS
$370M
| – | – |
-230,273
| Closed | -$2.68M |
|
|
AVDL
45
Avadel Pharmaceuticals
AVDL
$1.45B
| – | – |
-223,660
| Closed | -$3.78M |
|
46
CG Oncology
CGON
$2.08B
| – | – |
-40,723
| Closed | -$1.79M |
|
|
CRGX
47
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-51,126
| Closed | -$1.14M |
|
48
Dianthus Therapeutics
DNTH
$755M
| – | – |
-43,456
| Closed | -$1.3M |
|
49
Disc Medicine
IRON
$2.08B
| – | – |
-60,129
| Closed | -$3.74M |
|
50
Krystal Biotech
KRYS
$4.23B
| – | – |
0
| – | – |
|